NeuroPace (NASDAQ:NPCE – Get Free Report) is one of 511 publicly-traded companies in the “Healthcare Equipment & Supplies” industry, but how does it compare to its rivals? We will compare NeuroPace to related companies based on the strength of its profitability, earnings, analyst recommendations, valuation, dividends, risk and institutional ownership.
Institutional and Insider Ownership
78.8% of NeuroPace shares are owned by institutional investors. Comparatively, 40.5% of shares of all “Healthcare Equipment & Supplies” companies are owned by institutional investors. 19.2% of NeuroPace shares are owned by insiders. Comparatively, 14.8% of shares of all “Healthcare Equipment & Supplies” companies are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
Risk and Volatility
NeuroPace has a beta of 1.98, meaning that its share price is 98% more volatile than the S&P 500. Comparatively, NeuroPace’s rivals have a beta of 2.56, meaning that their average share price is 156% more volatile than the S&P 500.
Analyst Ratings
This is a summary of recent ratings for NeuroPace and its rivals, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| NeuroPace | 1 | 1 | 6 | 1 | 2.78 |
| NeuroPace Competitors | 4266 | 10510 | 18262 | 826 | 2.46 |
NeuroPace presently has a consensus target price of $20.50, suggesting a potential upside of 57.94%. As a group, “Healthcare Equipment & Supplies” companies have a potential upside of 18.40%. Given NeuroPace’s stronger consensus rating and higher probable upside, analysts clearly believe NeuroPace is more favorable than its rivals.
Valuation and Earnings
This table compares NeuroPace and its rivals gross revenue, earnings per share and valuation.
| Gross Revenue | Net Income | Price/Earnings Ratio | |
| NeuroPace | $99.99 million | -$21.47 million | -22.77 |
| NeuroPace Competitors | $1.89 billion | $138.79 million | 11.20 |
NeuroPace’s rivals have higher revenue and earnings than NeuroPace. NeuroPace is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.
Profitability
This table compares NeuroPace and its rivals’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| NeuroPace | -19.34% | -105.64% | -16.51% |
| NeuroPace Competitors | -278.16% | -150.10% | -21.89% |
Summary
NeuroPace beats its rivals on 9 of the 13 factors compared.
About NeuroPace
NeuroPace, Inc. operates as a medical device company in the United States. The company develops RNS system, a brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source for treating medically refractory focal epilepsy. It also records continuous brain activity data and enables clinicians to monitor patients in person and remotely. Its RNS System includes RNS neurostimulator, cortical strip and depth leads, and Patient Remote Monitor, as well as other implantable and non-implantable accessories. The company sells its products to hospital facilities for initial RNS system implant procedures and for replacement procedures. NeuroPace, Inc. was incorporated in 1997 and is headquartered in Mountain View, California.
Receive News & Ratings for NeuroPace Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NeuroPace and related companies with MarketBeat.com's FREE daily email newsletter.
